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Abstract
Background: There is increasing demand for rapid reviews and timely evidence synthesis. The goal of this project
was to understand end-user perspectives on the utility and limitations of rapid products including evidence
inventories, rapid responses, and rapid reviews.
Methods: Interviews were conducted with key informants representing: guideline developers (n = 3), health care
providers/health system organizations (n = 3), research funders (n = 1), and payers/health insurers (n = 1). We elicited
perspectives on important characteristics of systematic reviews, acceptable methods to streamline reviews, and uses
of rapid products. We analyzed content of the interview transcripts and identified themes and subthemes.
Results: Key informants identified the following as critical features of evidence reviews: (1) originating from a
reliable source (i.e., conducted by experienced reviewers from an established research organization), (2) addressing
clinically relevant questions, and (3) trusted relationship between the user and producer. Key informants expressed
strong preference for the following review methods and characteristics: use of evidence tables, quality rating of
studies, assessments of total evidence quality/strength, and use of summary tables for results and conclusions. Most
acceptable trade-offs to increase efficiencies were limiting the literature search (e.g., limiting search dates or
language) and performing single screening of citations and full texts for relevance. Key informants perceived rapid
products (particularly evidence inventories and rapid responses) as useful interim products to inform downstream
investigation (e.g., whether to proceed with a full review or guideline, direction for future research). Most key
informants indicated that evidence analysis/synthesis and quality/strength of evidence assessments were important
for decision-making. They reported that rapid reviews in particular were useful for guideline development on
narrow topics, policy decisions when a quick turn-around is needed, decision-making for practicing clinicians in
nuanced clinical settings, and decisions about coverage by payers/health insurers. Rapid reviews may be more
relevant within specific clinical settings or health systems; whereas, broad/national guidelines often need a
traditional systematic review.
Conclusions: Key informants interviewed in our study indicated that evidence inventories, rapid responses, and
rapid reviews have utility in specific decisions and contexts. They indicated that the credibility of the review
producer, relevance of key questions, and close working relationship between the end-user and producer are
critical for any rapid product. Our findings are limited by the sample size which may have been too small to reach
saturation for the themes described.
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Background
Rapid reviews are a form of evidence synthesis that may
provide more timely information for decision-making
compared with standard systematic reviews. Systematic
reviews are defined as “a review of a clearly formulated
question(s) that uses systematic and explicit methods to
identify, select, and critically appraise relevant research,
and to collect and analyze data from the studies that are
included in the review” [1]. While systematic reviews are
comprehensive, they can take on average one to 2 years
to complete [2, 3] and involve a substantial amount of
resources to produce according to current standards [4].
Rapid reviews “are literature reviews that use methods
to accelerate or streamline traditional [systematic re-
view] processes” in order to meet the needs and time-
lines of the end-users (e.g., “government policymakers,
health care institutions, health professionals, and patient
associations”) [2].
In 2014, a project conducted through the Evidence-
based Practice Center (EPC) Program of the U.S.
Agency for Healthcare Research and Quality (AHRQ)
explored the range of products that are considered
rapid [5, 6]. AHRQ “is the lead federal agency charged
with improving the safety and quality of America’s
health care system” (http://www.ahrq.gov/cpi/about/
profile/index.html). AHRQ produces evidence to im-
prove the safety and quality of the U.S. health care sys-
tem through its Effective Health Care Program
(EHCP), and “works within the U.S. Department of
Health and Human Services and with other partners to
make sure that the evidence is understood and used”
(http://www.ahrq.gov/cpi/about/profile/index.html). Institu-
tions in the USA and Canada serve as EPCs under contract
to produce evidence reports that are used to inform “cover-
age decisions, quality measures, educational materials and
tools, clinical practice guidelines, and research agendas”
(http://www.ahrq.gov/research/findings/evidence-based-rep
orts/overview/index.html). The Scientific Resource Center
(SRC) supports the EHCP by providing scientific and
technical support to protect scientific credibility and indepe
ndence of EHCP products (https://effectivehealthcare.ahrq.-
gov/index.cfm/who-is-involved-in-the-effective-health-care-
program1/about-the-scientific-resource-center1/).
In the 2014 project, we identified and examined 36 dif-
ferent rapid products from 20 organizations worldwide
and interviewed 18 producers of rapid products [5]. A
careful analysis led to a practical classification, or tax-
onomy, of rapid products according to the extent of syn-
thesis (Fig. 1): inventories, rapid responses, rapid
reviews, and automated approaches. A key finding was
the observation, based on interviews with 18 producers
of rapid reviews, that one of the biggest differences of
rapid products compared with standard systematic re-
views was the relationship between the review producer
and the end-user. The paper noted that “rapid products
are often conducted to help a specific end-user make a
specific decision in an identified timeframe; therefore,
the reviewers need to make decisions about what they
Fig. 1 Taxonomy of rapid products. This taxonomy provides general descriptions of rapid products based on a previous analysis of 36 different
rapid products from 20 organizations worldwide [5]. We recognize that there may be some overlap in individual products
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can provide in the time allowed.” This often necessitates
a direct relationship with a specific end-user with itera-
tive feedback throughout the project to manage the
scope (i.e., in terms of number and extent of research
questions, outcomes, etc.) and agree on acceptable
methodological approaches and trade-offs.
Our previous research focused on producers of rapid
products; in the present project, we were interested in
gaining an understanding of end-user perspectives on
rapid products. We undertook the present work to in-
vestigate the acceptability to end-users of different rapid
products and the context in which particular products
may be useful. Our objectives were to determine:
(1)What makes end-users trust and value an evidence
synthesis, and whether this varies by the nature of
the decision being made;
(2)End-user impressions of different rapid products
with a focus on acceptability and usability (e.g.,
impressions with respect to strengths and
limitations; trade-offs in terms of approaches they
would find acceptable to alter to increase efficien-
cies; and their perceptions of risks for answers being
“wrong” or information that might be missed);
(3)Where/when/how end-users might use rapid prod-




A workgroup of 17 members from 8 EPCs, the SRC, and
AHRQ participated in twice monthly teleconference calls
over the course of 10 months to discuss project direction
and scope, assign and coordinate tasks, collect and analyze
data, and discuss and edit draft documents [7]. Work-
group members brought a range of clinical and methodo-
logical expertise and had extensive collective experience
producing systematic reviews, other forms of evidence
syntheses (including rapid products), and working with
stakeholders to put evidence into practice. We undertook
a qualitative study involving in-depth interviews to gather
end-user perspectives of rapid products and identify
themes. Qualitative interviews allow the interviewer to ob-
tain the information sought, and due to their open-ended
nature, they also provide the opportunity for the inter-
viewer to probe for greater depth and clarity and for the
respondent to elaborate or provide examples to illustrate
concepts and perspectives [8]. Detailed methods and re-
sults are available in the full report [9].
Key informant selection and interviews
To ensure that study findings would be relevant to the
AHRQ EPC Program (the funder of this project) and
that key informants would be familiar with standard
review methods, we used purposive sampling and fo-
cused on frequent end-users of EPC reviews. Through
discussion, the workgroup members identified different
types of organizations that may use EPC reviews: re-
search funders, payers/health insurers, health system/
health care provider organizations, and societies/associa-
tions (e.g., that produce guidelines). We then identified
12 organizations representing these different stake-
holders. We approached individuals from these organi-
zations and invited them to participate in an interview
(Additional file 1: Appendix A). Prior to the interviews,
each key informant completed a conflict of interest form;
no disclosed conflicts precluded participation. All key in-
formants were familiar with or had used EPC reports
(i.e., traditional systematic reviews). While we did not
specifically select organizations or participants based on
their experience with rapid products, some participants
did have experience with rapid products.
One workgroup member (J-MG) conducted all inter-
views between January and March 2015 using a semi-
structured interview guide designed to elicit a multi-faceted
understanding of the value and uses of rapid products. The
interviewer is a physician scientist with extensive experi-
ence in quantitative and qualitative methods, including the
production of systematic reviews, stakeholder engagement,
and in-person and telephone interviews. Prior to the inter-
view call, participants were sent the interview questions
and samples of rapid products (evidence inventory, rapid
response, rapid review, and full EPC evidence report) that
would be discussed. The interviews lasted approximately
1 hour and were attended by at least two additional work-
group members. All interviews were digitally recorded and
transcribed verbatim.
Interview guide
The workgroup developed the interview guide, consisting
of open-ended questions (Additional file 1: Appendix B),
through a review and discussion of multiple iterations.
The workgroup discussed general concepts that we
wanted to address in the interviews, several members of
the workgroup drafted the interview guide, all workgroup
members provided feedback, and we discussed with the
full workgroup to ensure face validity. We wanted to
understand how our key informants used traditional sys-
tematic reviews and what they valued in these products
(e.g., what made the systematic reviews trustworthy or re-
liable, what components were most critical to informing
their decisions) (objective 1). We were also interested in
their impressions of the different rapid products (evidence
inventory, rapid response, rapid review—see Fig. 1) (ob-
jective 2), as well as whether they would consider any of
the rapid products useful and, if so, in what context (e.g.,
for specific decision-making needs) (objective 3). In par-
ticular, we wanted to know (a) what trade-offs they would
Hartling et al. Systematic Reviews  (2017) 6:32 Page 3 of 11
be willing to accept to increase efficiencies in the produc-
tion of reviews (objective 2), and (b) what risks they per-
ceived might be incurred with rapid approaches (e.g.,
inaccurate findings, missing studies) (objective 2).
Sample rapid products
From an initial list of 11 EPC systematic reviews ad-
dressing topics considered to be of general interest and
completed in the last 2 to 3 years, we reached consensus
and selected four potential review topics: venous
thromboembolism, fecal DNA testing, pressure ulcers,
and methicillin-resistant staphylococcus aureus. We
then searched to identify rapid products on these topics
through agencies we knew produce rapid products. We
looked for examples that reflected the key categories of
rapid products (inventories, rapid response, rapid re-
view) identified in our previous work (Fig. 1) [5]. We
found the highest number and the broadest range of
rapid products for venous thromboembolism and chose
among these to represent the three rapid products to
share with the key informants. The evidence inventory
was produced by the Canadian Agency for Drugs and
Technologies in Health, [10] the rapid response was pro-
duced by ECRI Institute, [11] and the rapid review was
produced by the Penn Medicine Center for Evidence-
based Practice [12, 13]. These three organizations have
extensive experience producing rapid products. The full
EPC systematic review on the same topic is available on
the AHRQ website [14].
Data analysis
Transcripts were independently analyzed using content
analysis with NVivoTM software by two investigators
trained in qualitative analyses (MLM, JA). Two other in-
vestigators with experience in qualitative analysis inde-
pendently reviewed all transcripts and verified themes
and subthemes (J-MG, LH). To ensure reliability of the
coding structure, all themes and subthemes were also
reviewed in the larger multi-disciplinary workgroup.
We adhered to methodologically sound qualitative re-
search methods including independent reviews of texts,
thematic coding by qualitatively-trained reviewers, and
convergence of interpretation across a multi-disciplinary
team of researchers. Our analysis was guided by principles
of grounded theory, wherein an understanding of the con-
cept of interest arises from the empirical data rather than
from a priori hypotheses. Two trained qualitative analysts
independently analyzed responses to identify and code
themes and subthemes. After a preliminary review of the
data, the investigators developed an initial list of codes,
which were modified and expanded as the analysis pro-
gressed. To ensure reliability of the coding structure, all
themes and subthemes were reviewed with the larger
multi-disciplinary research team which included experts
in evidence reviews, rapid reviews, stakeholder engage-
ment, clinical care, and research.
Results
A total of eight interviews were conducted with U.S. or-
ganizations representing: guideline developers (n = 3),
health care providers (n = 3), research funder (n = 1), and
non-commercial payer/insurer (n = 1). Four individuals
who were invited to participate did not respond. For one
of the organizations represented by those who did not
respond, we approached two alternate potential partici-
pants who declined as they felt their input would not be
relevant or helpful. Finally, one individual who had
agreed to participate had to withdraw because of a last-
minute scheduling conflict.
Six of eight key informants had clinical backgrounds;
of these, two produced guidelines for professional orga-
nizations, two represented health systems, one was a
funder, and one represented a non-commercial payer.
Two key informants were non-clinical; one produced
guidelines for a professional group and the other repre-
sented a health system. All key informants routinely
commissioned and used systematic reviews. There was
varied representation with respect to knowledge and use
of rapid review products: three key informants were in-
volved in producing rapid review products, two key in-
formants used rapid review products, and three key
informants were unaware of or had no experience using
rapid review products.
Users’ perspectives on important characteristics of
reviews (objective 1)
Key informants were asked what they considered the most
important characteristics of review products for their use.
Themes that emerged (Table 1) were related to methods,
source of the review, relationship between producer and
user, clinical significance of the review questions, and the
recency of the review. The most commonly reported
review characteristics deemed critical were (1) the review
was conducted by a reliable source, i.e., conducted by ex-
perienced reviewers from an established research
organization (all key informants); (2) the review addressed
clinically relevant questions (all key informants); and (3)
there was a relationship between the user and producer of
the review (seven of the eight key informants; one key in-
formant did not discuss). Other important review charac-
teristics that were noted included recency of the review
and use of sound methodology (each item was noted by
four key informants and not mentioned by four key
informants).
Users’ perspectives on review methods (objective 2)
Table 2 presents themes and sample quotes regarding the
key informants’ perspectives on individual components of
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a review. Key informants felt that the following were very
important: quality rating of studies (noted by seven key in-
formants; not mentioned by one key informant), data ta-
bles (including characteristics of included studies) (noted
by four key informants; not mentioned by four key infor-
mants), assessment of overall quality/strength of evidence
(noted by five key informants; not mentioned by three key
informants), and use of summary tables of results and
conclusions (noted by three key informants; not men-
tioned by five key informants). One key informant (re-
search funder) mentioned that specific recommendations
regarding future research needs were important for use in
research development and funding.
The most commonly reported acceptable trade-offs to
increase efficiencies were associated with the literature
search (all six key informants who mentioned literature
search agreed that limits on such items as date or lan-
guage were acceptable) and citation and full-text review
(among five key informants who discussed this point,
four agreed that a single review was acceptable, and one
agreed depending on the expertise of the individual
doing the review). The majority of key informants were
willing to accept shortcuts made in these areas in ex-
change for a shorter production time.
Users’ perspectives on uses of rapid products (objective 3)
Key informants reported a variety of potential uses for
rapid products and standard systematic reviews (Table 3).
Several stated that the evidence inventory (three key in-
formants; guideline developers, provider organization)
and rapid response (four key informants; guideline de-
velopers, research funder, provider organization) would
not be useful for their purposes, while other key infor-
mants considered these useful for new topics, to under-
stand the depth and/or breadth of existing evidence/
available literature, for restricted local use, or for clini-
cians who are already familiar with the literature in a
topic area. When key informants did see utility in the
rapid products, they were more often viewed as interim
products (or “placeholders”) to inform downstream in-
vestigation (e.g., whether to move forward with a full re-
view or a guideline, direction for future research/
funding); the rapid products were viewed less commonly
as useful for “end-point” decisions (especially the
Table 1 Key informant interviews: important characteristics of reviews
Element Theme Sample quotes [type of end-user]
Methods Important that sound methods are used in developing
review
“..adherence to good standards of evidence evaluation is really
critical, so that probably matters more to me than anything”
[provider]
Source Trust review products from reliable sources “If it came from a place that we trust then we would have more
confidence in using it than if it was just arbitrarily out there from
somebody who had done it once.” [guideline developer]
“the source is always really important, knowing that someone is
evaluating the evidence in a rigorous way, the way that we do





Important to establish relationship with user up front “… the quality that we've had in the reviews when they have
that connection up front is significantly different…I think it also
helps build trust in how the evidence is being done.” [guideline
developer]
“…I think it’s incredibly important for the guideline developers to
be involved from day one.” [guideline developer]
Clinical
significance
Reviews should include considerations of clinical importance,
not just statistical significance
“…ultimately, the clinical aspect is important. There is sometimes
a gap between the statistical significance versus what’s clinically
significant…” [guideline developer]
Recency Important that a report is recent. A gap search is
sometimes done
‘We’re usually hoping we find something within the last two to
three years” [guideline developer]
“We’re certainly willing to do the bridge look search to make sure
that there hasn’t been something big that’s come up that might
adjust the estimated treatment effects” [guideline developer]
Key questions The framing of the question can be the most important aspect
of a review
It is important that the key questions address what the end-
user needs, including clinical outcomes and consideration of
benefits and harms
Narrowing the scope of the key questions can sometimes be
problematic
“…the thing that I find most helpful in this approach to evidence
always is the framing of the question” [provider]
“…we want to make sure that the questions that were addressed
are what the guideline developers interested in terms of just
plain old clinical outcomes” [guideline developer]
“When I’ve used some other Rapid Reviews, when they narrow
the scope they probably at least half the time completely miss
the mark of the question we want answered. Keeping it a little
bit broader would be something that I would not sacrifice…”
[payer]
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evidence inventory and rapid response). Moreover, some
key informants commented that the level of detail avail-
able in the evidence inventory and rapid response was
not sufficient for decision-making; most key informants
indicated that analysis/synthesis and assessment of
overall quality/strength of evidence was important to
this end.
All but one key informant indicated that they could
see a use for a rapid review, in particular, for guideline
development (particularly for narrow topics), policy
Table 2 Key informant interviews: perspectives on review methods
Element Theme Sample quotes [type of end-user]
Literature search It is okay to limit the search by database, journal,
year, etc. as long as it is scientifically justified
“I’d probably be more comfortable with selecting top 20 [journals]…and just
do the evidence review using those.” [guideline developer]
“I would not expect things like looking for unpublished literature.” [payer]




It is acceptable to have single review of abstracts
and full text
“To me that [single review] would be acceptable.” [research funder]
“I think implicitly in these kinds of rapid reviews…you’re going to do a
combination of looking at existing reviews so that will help catch stuff that
you might otherwise miss with single review.” [provider]
Quality
assessment
Some assessment of literature quality is necessary “I think that [quality assessment] should be included.” [payer]




Evidence tables are useful “I think the most important part of an evidence review is always going to be
the evidence tables” [guideline developer]




Quality/strength of evidence is important “That [strength of evidence grading] would be very important.” [payer]
“The strength of the evidence I always find valuable as well.” [provider]
Summary tables Summary tables or ways to present the results/
conclusions in an accessible format are useful
“A lot of times you’ll do good summary tables, and that’s probably where I
would look…” [payer]
“The work development teams in our clinical programs are more concerned
with what’s the summary of the evidence.” [provider]
Future research
recommendations
Future research recommendations are helpful for
research development
“…what are the future research recommendations…99.9% of the systematic
reviews all concluded more research is needed, so focus on exactly what are
they recommending.” [research funder]
Comments that are italicized represent most acceptable trade-offs
Table 3 Key informant interviews: uses of rapid products and standard systematic reviews
Use Evidence inventory Rapid response Rapid review Systematic review
For broad topic areas/population issues X
To inform research agenda X
For in-depth understanding of a topic area X
For guideline or recommendation development X X
For guideline/recommendation updates or new
issues subsequent to a guideline/recommendation
X X
For coverage decisions X X
For organizational or policy change X X
For implementation X X
For quick decisions X
When no previous SR or guidance exists X
For “hot” or timely topics X X
In area with limited literature X X
To understand depth and/or breadth of evidence
e.g., evidence maps
X X
To clarify whether a review is already available X X
To ignite/catalyze change or challenge the status quo X X
Hartling et al. Systematic Reviews  (2017) 6:32 Page 6 of 11
decisions when a quick turn-around is needed, decision-
making in nuanced clinical settings and for practicing
clinicians, and coverage decisions. Most key informants
felt that standard systematic reviews cannot be used for
quick decisions, unless they already exist, in which case
they often need a bridge search. Key informants noted
factors to be considered when using a rapid review, in-
cluding that the review must (a) have quality methods
and/or be from a reliable source and must also (b) ad-
dress specific questions/clinical outcomes of interest.
Generally, a traditional systematic review is preferred
but in cases where none exists, Key informants are will-
ing to accept rapid reviews for shorter turn-around. Key
informants noted limitations with rapid reviews in terms
of evaluating the spectrum of benefits and harms often
needed for their decision-making purposes, and limited
detail with respect to important subgroups.
Another theme that emerged is that rapid responses
and rapid reviews may be more relevant for issues (often
narrow questions) that arise within the clinical setting
specific to a health system (where it may be more feas-
ible to narrow the scope), or when interest is focused
more on implementation (e.g., tailoring the evidence to
a given region/setting). Conversely, key informants felt
that broad/national guidelines more often need a full
systematic review. The following comment highlights
this perspective (guideline developer):
So that’s the dichotomy to me is that there are people
working on implementation and what’s going to
happen out in our system of care delivery; and there
are people working on trying to make sure that what
we’re saying is the right thing to be doing and there’s
a tension between that. We’ve often talked about the
struggle to balance rigor with efficiency and so the
operationally-oriented folks are willing to take a risk
on the absolute correctness and the answer in order
to do something and to do it reliably across the deliv-
ery system where the more traditional EBM people
and guideline people would really rather take the time
to make sure they know that they’ve got the right
answer.
Many of the key informants emphasized that an evi-
dence review is just one part of the decision-making
process. There are many other factors considered, in-
cluding cost and feasibility.
Discussion
Our study provides information about how end-users
perceive different types of rapid products and what fea-
tures are the most important (Table 4). We specifically
asked key informants who use AHRQ-sponsored system-
atic reviews about three different rapid review types
(evidence inventory, rapid response, and rapid review;
Fig. 1). Our results suggest that each product type could
prove useful under specific circumstances; further, key
informants were more likely to consider them useful if
they had previous direct experience using them. The fol-
lowing observations were made for the specific rapid re-
view products.
 Evidence inventory: Although some of the key
informants saw value in this product, it was
generally not considered sufficient to inform
decision-making because it did not “give an answer
to the question” or a synopsis of the evidence. Some
key informants indicated that an evidence inventory
may be useful to stimulate discussion, to challenge
the status quo, or to get a sense of the literature
when there is a pressing concern. These situations
were typically in the context of a hospital system.
 Rapid response: Few of our key informants found
this product to be sufficient for their decision-
making needs although they did prefer this to an
evidence inventory. A perceived use for a rapid re-
sponse was to validate the need for future research
or a rapid or traditional review (e.g., identify the vol-
ume of research in a given area and whether there is
consistency in terms of benefits).
 Rapid review: Most of the key informants liked rapid
reviews and generally considered this to be
acceptable when a traditional systematic review is
unavailable. While guideline developers generally
wanted something more comprehensive and
detailed, they felt rapid reviews may be used for
guidelines on narrow topics, updates of guidelines,
or for new issues that arise subsequent to a
guideline or recommendation. Other end-users (e.g.,
payer/insurer) were less concerned about compre-
hensiveness. Positive aspects of the rapid review in-
cluded its conciseness and a focus on existing
syntheses and high quality studies. This was consid-
ered useful for policy decisions that were time-
dependent.
Our findings reaffirm that an interactive and ongoing
relationship ensures that products meet end-user’s
needs, particularly for the development of key questions
that the review aims to answer [15]. Further, our findings
confirm that trust is an important factor in the usability
of rapid reviews, and this trust is based on both the
established reputation of the producer and on how the
producer works with the end-user iteratively over the
course of refining/scoping the topics and producing the
review or reviews to meet their specific decision-making
needs. This places the responsibility for the reliability
and validity of the product in the hands of the
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producers. Producers need to ensure that rapid products
use transparent methods that communicate potential
limitations and risks to end-users [16]. In addition, pro-
ducers should be aware of the potential harm that a mis-
leading conclusion from a rapid product might have on
their reputation [17].
End-users are willing to accept trade-offs in review
methods, such as limiting the literature search and con-
ducting single screening of abstracts and full text, in
order to get more timely information to support deci-
sions. For the scientific systematic review community,
eliminating key procedures meant to reduce reviewer er-
rors and bias represents an important variation from
standard SR methodology [18]. This raises two import-
ant questions that can only be answered through empir-
ical research. First, to what extent do these shortcuts
reduce the validity of the final conclusion? There has
been limited empirical research on the incremental
validity of systematic review methods [19–24]; moreover,
very few studies have compared the conclusions reached
in rapid reviews vs. systematic reviews [25, 26]. A second
empirical question is how much time is actually saved by
different methodological shortcuts. For instance, our key
informants agreed that limits to the literature search
would be acceptable (e.g., date or language restrictions);
however, it is not known how much time this would ac-
tually save. We recognize the challenge of conducting
empirical comparisons of SRs and rapid products, par-
ticularly given the variability in topics and contexts in
which both are generated. If it is feasible to collect these
kinds of data, it may be possible to make more informed
decisions about the benefits and risks of rapid review
products in different contexts.
According to our key informants, other characteristics
of the review product also appear to significantly con-
tribute to the usability of the product, such as quality
Table 4 Key informant interviews: themes about review products




Producer Trust • This was the primary issue that arose in the context of how end-users
valued a review, and whether they would rely on a rapid product
• Methodological alterations appear to be secondary to the trust
established through consistent products and active end-user
engagement
Producer Close working relationship • Maintaining a close working relationship between the end-user and
the review producer was considered important to ensure that the key
questions reflected the end-user’s needs
Report Relevance of the key questions • Key informants stressed this, noting that if questions did not directly
address the specific end-users’ needs, the review was of little or no
value, regardless of the methods used
Report Quality/strength of evidence and evidence
tables
• Several key informants found these elements to be essential and
often the most valuable part of the reports
• End-users liked to see outcome data, individual study quality, and
overall quality/strength of evidence assessment summarized in a
readily accessible form
Report Responsibility of reviewers to highlight
methodological considerations/limitations
• Reviewers need to help users understand potential ramifications of
streamlined methods as end-users may not be aware of standard re-
view steps and accepted methodological approaches
Decision Ability to easily change or reverse a decision • May be one hallmark of when a rapid product is useful
• For example, key informants expressed that a full systematic review is
more often necessary for clinical practice guidelines, broad
application of the evidence (e.g., “change the direction of the
organization on a very important topic”), or macro topics (e.g.,
population-level implementation)
• Conversely, a rapid product may be sufficient: for decisions being
made on a local basis (e.g., point-of-care clinical decisions, nuanced
clinical situations, local coverage decisions) where there is not the
same level of scrutiny; for “in the moment sort of decisions”; to act as
an update for a previous comprehensive guideline or address an
issue that comes up secondary or subsequent to a guideline; or to
get a general sense of the literature or scale of the issue
Decision There is generally more than the evidence of
benefits and harms to consider when making a
decision
• Rapid products provide one source of information among an array of
other considerations for decision-making
• Other factors include context and varied viewpoints, the burden of
disease and population affected, and costs.
• Due to these other factors, there may be less perceived risk of using
a rapid product
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assessment of included studies (payer and provider), the
use of evidence and summary tables (guideline devel-
opers), assessment of the quality/strength of the evi-
dence base as a whole (payer and provider), and future
research recommendations (research funder). The trade-
off of reducing or removing these aspects of reviews to
gain efficiencies may result in the review being less val-
ued by some end-users. Further, if all these elements are
desired (or required), it may be more likely that re-
viewers can gain efficiencies through focusing the scope
and questions of the review.
Strengths and limitations
We followed sound qualitative methodology in eliciting
perspectives from different types of users and in identify-
ing themes. However, our small sample size (ideally 12–15
in qualitative research to identify patterns [10]) means that
results are likely not representative of all end-users and
we cannot be sure that the themes reached saturation.
This is especially true in considering whether there are
differences in the perspectives across and between types
of users. Further, key informants included some individ-
uals who had not used rapid products; therefore, their per-
spectives on the value and uses of rapid products are
hypothetical. The hypotheses generated from this work
need further evaluation. A further limitation is our selec-
tion of a sample of rapid products from known producers.
Our sample of products was chosen based on our know-
ledge of the various rapid products and methods gained
through our previous research [5]. Informants’ views may
not be generalizable to all rapid products or those on
other topics.
We chose to interview frequent and known users of
AHRQ comprehensive systematic evidence review
products. It may be that infrequent users or more var-
ied audiences would have different perspectives. For
instance, users with less experience in traditional sys-
tematic review methodology would perhaps find fewer
limitations and more value in rapid review products.
Eliciting views from additional audiences, such as
those for whom the rapid products were designed,
may also help in understanding obstacles or benefits
to using rapid review products. However, current users
of AHRQ products provide a critical perspective as
they are knowledgeable about systematic review meth-
odology, have a high standard for evidence synthesis,
and may be considered a key audience for rapid review
products.
Future directions
We did not systematically compare the needs and values
of different end-users; further, there are other perspectives
we did not collect, including those from frontline clini-
cians, patients, and infrequent users of AHRQ products.
Conducting interviews or focus groups with a larger num-
ber of more diverse users and incorporating patient per-
spectives would allow differences to be explored and
enable the evaluation of hypotheses identified in this work.
Interviewing a range of stakeholders at the same time, and
having informants share their different decision-making
contexts, may elicit important contrasts and insights
about the usefulness of rapid products.
We were also unable to identify specific trade-offs that
would be acceptable to end-users. A more structured
survey of end-users, as well as producers, may provide
more information about trade-offs. These types of ques-
tions could elucidate what would be acceptable in terms
of time or other resource trade-offs for the inclusion of
a specific review methodology or characteristic. Under
what circumstances, for what questions, would end-
users trust a specific type of rapid review product? The
key to collecting valid information is that end-users
understand the steps involved in a review as well as em-
piric evidence of the impact of alternative methods on
results and conclusions.
Ideally, future studies would also move beyond hypoth-
esis generation towards empirical testing. One possible de-
sign is the completion of systematic reviews and rapid
review products on the same questions; a study of this
nature, the SPARKS Study, has recently been funded by the
Canadian Institutes of Health Research (http://webapps.cih
rirsc.gc.ca/cris/detail_e?pResearchId=7016266&p_version=
CRIS&p_language=E&p_session_id=2514166). Ultimately,
we would want to know how long it takes to produce each
product, whether these different review products were
more or less useful for end-users in informing decisions,
and most importantly, if those decisions would be different
depending on the product used.
Empirical research on the impact of streamlining spe-
cific methodological approaches is essential given the
finding that changes to methodological approaches ap-
pear to be acceptable to end-users as long as trust is
established through consistent products and active end-
user engagement, and there is clear communication by
producers about methods and the potential ramifications
of streamlined methods.
Finally, this and our previous work on rapid reviews
have identified a wealth of information contained within
these rapid products that could be useful to stakeholders
beyond those commissioning the specific rapid reports.
However, there is no central repository for rapid products.
Many are not published in traditional peer-reviewed
sources, indexed in bibliographic databases, or digitally
archived. While some are publically available on the web-
sites of review producers, others are only available upon
request or subscription. Discussion among the community
of rapid review producers to explore the potential for a
central repository is warranted [27].
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Conclusions
Evidence inventories, rapid responses, and rapid reviews
have utility in specific decisions and contexts. For any
rapid product, the credibility of the review producer,
relevance of key questions, and close working relation-
ship between the end-user and producer are critical.
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